Jumo Health Launches PRISM™, Defining a New Category of Readiness-Based Clinical Trial Execution.

NEW HAVEN, Conn. — January 29, 2026

Jumo Health, a Patient Experience Organization, announced the launch of PRISM™, a readiness-based clinical trial recruitment, enrollment, and retention system designed to address one of clinical research's most persistent and costly execution gaps.

Clinical research has invested heavily in finding eligible patients, expanding reach, improving matching, and accelerating screening. Yet patients still fail to advance, enrolled participants still withdraw, sites still absorb preventable rework, and sponsors still fund rescue activity.

PRISM was created around a different operating premise: medical eligibility does not establish whether a patient is cognitively, emotionally, practically, and behaviorally prepared for the realities of participation. Readiness must be evaluated, developed, and governed across the journey rather than assumed at enrollment.

Why eligibility-first execution breaks down.

Conventional trial systems are designed to optimize entry. Recruitment platforms scale reach and response. Eligibility tools identify protocol fit. Engagement programs deliver information and reminders. Each capability matters, but none alone determines whether participation will remain viable once the trial's burden becomes real.

A medically eligible patient may still misunderstand study requirements, underestimate travel or scheduling demands, lack caregiver support, distrust the process, or be unprepared for the emotional weight of participation. When those conditions surface after screening or enrollment, the study has already paid to advance an unstable decision.

That instability appears downstream as screen failure, missed visits, protocol deviations, early withdrawal, site escalation, forecast volatility, or rescue recruitment. PRISM is designed to expose and address the readiness conditions underneath those outcomes earlier.

PRISM changes what trial execution governs.

PRISM shifts the operating question from whether a patient can qualify to whether participation can hold. It integrates readiness intelligence with patient education, behavioral diagnosis, pre-screening, advancement, site handoff, retention monitoring, and targeted intervention.

Rather than treating recruitment, enrollment, and retention as separate activities, PRISM connects them as one progression system. Readiness is assessed before advancement, strengthened when barriers can be addressed, validated before site handoff, and monitored as participation conditions change.

What PRISM enables.

PRISM supports clinical operations teams across six connected execution needs:

• Patient identification. Locate medically eligible patients using claims, EMR and EHR, laboratory, genetic, protocol, site, and provider data where appropriate.
• Readiness assessment. Identify structural, cognitive, emotional, behavioral, social, and protocol-related conditions that may prevent progression.
• Prioritization and development. Determine which patients can advance and which require education, expectation alignment, support, or pacing.
• Intelligent pre-screening. Apply protocol logic while validating whether participation is understood and practically feasible.
• Readiness-informed site handoff. Advance better-prepared patients with context that supports more productive screening and consent conversations.
• Retention and completion protection. Monitor burden, engagement, understanding, confidence, and support for signs of readiness deterioration.

A system built for governed progression.

PRISM is structured as an execution system rather than a static score, chatbot, media channel, or point solution. Its architecture connects data intelligence, patient experience, coordination, retention, and measurement so insight can lead directly to intervention.

The system is designed to work with sponsor, CRO, site, and clinical technology infrastructure. It does not replace clinical responsibility or site judgment. It moves preventable readiness work upstream and provides earlier visibility into the conditions likely to affect advancement and completion.

Defining readiness-based clinical trial execution.

The launch of PRISM formalizes a new operating category. The industry has historically treated readiness as a soft patient-engagement concept or an outcome inferred from consent and enrollment. PRISM treats it as infrastructure: a dynamic state that can be measured, strengthened, governed, and monitored.

This creates a different definition of trial performance. The objective is not more activity for its own sake. It is more productive referrals, stronger advancement, better-prepared site handoffs, earlier risk detection, more stable retention, and a lower cost per completer.

PRISM is available to biopharma sponsors and research partners across select therapeutic areas.